Trial Profile
A phase I repeated dose study of CAM2029 for treatment of patients with acromegaly, neuroendocrine tumors (NETs).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 May 2016
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly; Neuroendocrine tumours
- Focus Adverse reactions
- 06 May 2016 New trial record